Polymyxin: A Literature Course on What the Published Studies Report

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment, or medication. Nothing here is a protocol, a recommendation, or a claim of benefit. It is a structured reading of published papers so that a non-specialist can follow what researchers actually studied and what they reported.

Module 1: What Polymyxin Is and How It Has Been Studied

Polymyxins are a family of cationic cyclic lipopeptides of bacterial origin, isolated in the 1940s from the soil organism now classified as Paenibacillus polymyxa. Structurally they are not conventional small-molecule antibiotics: each molecule combines a cyclic heptapeptide ring, a short exocyclic peptide tail, and a fatty acyl chain. Several positively charged diaminobutyric acid residues give the molecule its strong cationic character, and that charge is central to how the literature explains its activity.

Two members reached clinical use: polymyxin B and polymyxin E, the latter usually called colistin and administered as the prodrug colistimethate. A 2019 chapter reviewing the clinical use of polymyxin B summarised how this agent has been positioned against multidrug-resistant Gram-negative infections and the practical issues that accompany it (Clinical Use of Polymyxin B). Beyond the natural products themselves, medicinal chemists have built synthetic analogues: a 2025 methods protocol described the synthesis of polymyxin-inspired peptidomimetics, that is, non-natural molecules designed around the polymyxin scaffold (Synthesis of Polymyxin-Inspired Peptidomimetics).

How the evidence base is shaped

Study types in this literature fall into a few recognisable groups:

• In vitro microbiology — susceptibility testing, combination screens, and resistance characterisation in clinical isolates.
• Biophysical and cell studies — how the molecule interacts with membranes, proteins, and ion channels.
• Case reports and case series — individual patients in whom clinicians documented an unexpected adverse event.
• Narrative reviews and book chapters — syntheses of clinical experience rather than new data.

Limits of the evidence in Module 1

Definitions and class descriptions are stable, but the modern polymyxin literature is unusually dependent on retrospective clinical experience, in vitro work, and single-patient reports. Large prospective randomised trials of polymyxins are scarce relative to how long these drugs have existed, partly because they were reintroduced late as salvage options rather than developed under contemporary trial standards.

Module 2: Mechanism as Described in the Literature

The mechanistic account most often given is electrostatic and structural. The cationic polymyxin molecule is described as binding the anionic lipopolysaccharide (LPS) of the Gram-negative outer membrane, displacing stabilising divalent cations, disorganising the membrane, and permeabilising the bacterial envelope. Because the target is an envelope component rather than a protein enzyme, the described activity is largely restricted to Gram-negative organisms whose outer membrane presents that LPS target.

Resistance mechanisms as reported

Studies have examined how bacteria escape this interaction. A 2019 report described the inactivation of polymyxin by a hydrolytic mechanism, adding enzymatic degradation to the list of described escape routes alongside LPS modification (Inactivation of Polymyxin by Hydrolytic Mechanism). A 2019 review framed emergent polymyxin resistance as a question of whether the polymyxin era was ending, situating resistance reports within the broader last-line antibiotic problem (Emergent Polymyxin Resistance: End of an Era?). A 2022 hospital study reported the prevalence and molecular characteristics of polymyxin-resistant Pseudomonas aeruginosa isolated in a Chinese tertiary teaching hospital, characterising the resistant population rather than testing a therapy (Prevalence and Molecular Characteristics of Polymyxin-Resistant Pseudomonas aeruginosa).

Off-target interactions

Two mechanistic strands concern host rather than bacterial targets. A 2022 study reported that inwardly rectifying potassium channels mediated polymyxin-induced nephrotoxicity, proposing a specific channel-level route for kidney injury (Inwardly rectifying potassium channels mediate polymyxin-induced nephrotoxicity). Separately, a 2021 biophysical chemistry study reported that polymyxin B accelerated the aggregation of α-synuclein, a protein of interest in neurodegeneration research, in an in vitro system (Polymyxin B accelerates the α-synuclein aggregation).

Limits of the evidence in Module 2

Membrane-disruption models are largely built from in vitro and biophysical systems, which cannot reproduce protein binding, tissue distribution, or immune interaction in a living host. The α-synuclein finding was a test-tube observation about protein aggregation kinetics, not a clinical neurodegeneration outcome, and the researchers did not establish that such aggregation occurs in treated patients. Channel-level nephrotoxicity mechanisms describe a pathway; they do not quantify individual risk.

Module 3: Reported Outcomes by Study

This module summarises what specific papers set out to measure and what they reported, without converting any of it into an expectation of benefit.

Reading combination studies carefully

The triple-combination work sits in a recognisable pattern: when single-agent activity fails, investigators test whether pairing or tripling agents restores measurable killing in the laboratory. The 2020 study examined polymyxin triple combinations specifically against polymyxin-resistant, multidrug-resistant, KPC-producing K. pneumoniae (Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae). An in vitro synergy signal is a laboratory endpoint. It is not a patient outcome, and the literature does not treat the two as interchangeable.

Limits of the evidence in Module 3

None of these reports was a randomised clinical trial with mortality or cure endpoints. Prevalence figures are specific to one institution and one time window and do not generalise to other regions. In vitro combination results depend heavily on inoculum, media, and the particular isolates tested. Synthetic methods papers report chemistry, not efficacy.

Module 4: Polymyxin Side Effects: What Studies Report

Toxicity is the most consistently documented feature of the polymyxin literature. The categories below are drawn from published mechanistic work, reviews, and case reports.

Kidney effects

Nephrotoxicity dominates the toxicity discussion. A 2022 study reported that inwardly rectifying potassium channels mediated polymyxin-induced nephrotoxicity, identifying a channel-dependent pathway in the kidney (PMID 35570209). The 2019 review of clinical polymyxin B use discussed nephrotoxicity as a central constraint on the clinical role of the drug (PMID 31364080).

Electrolyte and tubular disturbance

Two case reports described a Bartter-like presentation. A 2024 BMJ Case Reports paper reported polymyxin B-induced Bartter syndrome in a patient (PMID 38702070), and a separate 2024 report described polymyxin B-induced Bartter-like syndrome as an unusual adverse effect (PMID 39649859). Both were single-patient descriptions of renal tubular electrolyte disturbance temporally associated with polymyxin exposure.

Neuromuscular effects

A 2024 case report in Frontiers in Neurology described polymyxin-induced neuromuscular weakness in a single patient (PMID 38601335). Neuromuscular blockade has long been discussed alongside nephrotoxicity as a recognised polymyxin concern in clinical reviews (PMID 31364080).

Skin effects

A 2020 case report described polymyxin B-induced skin hyperpigmentation, a cutaneous adverse event documented in individual patients (PMID 33014066).

Limits of the evidence in Module 4

Case reports establish that an event was observed and considered plausibly drug-related; they cannot establish frequency, dose-dependence, or causation. Patients in these reports were typically critically ill and receiving multiple medications, so attribution is inferential. Mechanistic nephrotoxicity work identifies a pathway without predicting who will be affected. No page can convert this literature into an individual risk estimate.

Module 5: Pharmacokinetics Where Data Exist

Polymyxin pharmacokinetics are discussed in the clinical literature as unusually complicated for an old drug. The 2019 review of clinical polymyxin B use addressed the practical pharmacology of the agent alongside its toxicity and resistance profile (PMID 31364080). Several structural features explain why this matters: polymyxins are large, highly charged lipopeptides rather than small neutral molecules, which shapes distribution, protein binding, and elimination in ways that differ from most antibiotic classes. Polymyxin B and colistimethate also differ from one another, because colistimethate is administered as an inactive prodrug that must convert to colistin, whereas polymyxin B is given as the active sulfate.

This page deliberately does not reproduce dosing figures, infusion schedules, or target exposure values. Those parameters belong to prescribing information and to the clinicians who apply them to a specific patient, and the verified literature summarised here does not provide a quantitative dosing framework that could be restated responsibly in an educational setting.

What analogue chemistry contributes

Interest in polymyxin-inspired peptidomimetics is partly a pharmacokinetic and toxicity story: designers of such molecules have sought scaffolds that retain envelope activity while altering other properties, and a 2025 protocol set out the synthetic methods used to make them (PMID 40531465). Those are chemistry papers; they do not report human pharmacokinetics.

Limits of the evidence in Module 5

Pharmacokinetic understanding of polymyxins developed decades after the drugs entered use, and much of it comes from small studies in heterogeneous critically ill populations. Renal function, renal replacement therapy, and formulation differences all complicate comparison between studies. No pharmacokinetic dataset in the verified literature here supports statements about non-clinical or self-directed use, and none was collected in healthy volunteers for that purpose.

Module 6: Regulatory Status, Stated Factually

Polymyxins occupy a distinctive regulatory position: they are old approved drugs that predate modern approval standards, and they re-entered use as resistance narrowed the alternatives.

• Approved prescription products. Polymyxin B sulfate is an approved injectable antibiotic in the United States and other jurisdictions, and colistimethate sodium (polymyxin E) is likewise an approved injectable product. Both are prescription medicines used under clinical supervision.
• Topical and ophthalmic formulations. Polymyxin B also appears in approved topical and ophthalmic preparations, frequently in fixed combinations with other antibacterial agents, including some over-the-counter first-aid ointments.
• Research-use-only material. Polymyxin sulfates and polymyxin-inspired analogues are also supplied as laboratory reagents labelled for research use only. Research-use-only material is not an approved medicine, is not intended for human or veterinary administration, and is not subject to the manufacturing and labelling standards applied to drug products. Synthetic peptidomimetics of the type described in the 2025 methods protocol exist only as research chemicals (PMID 40531465).
• Compounding. In the United States, compounding of drug preparations is governed by federal law and state pharmacy regulation, and compounded preparations are not FDA-approved products even when the active ingredient appears in an approved drug. Compounding is performed by licensed pharmacies and outsourcing facilities under those rules.
• Stewardship framing. Regulatory and professional attention to polymyxins is closely tied to resistance; a 2019 review explicitly asked whether emergent polymyxin resistance signalled the end of the polymyxin era (PMID 31420655).

This regulatory summary is general information, not legal advice.

Limits of the evidence in Module 6

Regulatory status varies by country and changes over time; product labelling, approved indications, and available formulations differ between jurisdictions. Published research papers do not establish legal status, and the citations above describe science rather than policy.

What the Studies Did Not Test

Reading this literature as a whole, several gaps are explicit:

1. No wellness, performance, or longevity endpoints. Polymyxin research is antibacterial and toxicological. None of the cited work examined body composition, cognition, recovery, ageing, or any non-infectious outcome.
2. No healthy-population exposure studies. The cited clinical material describes patients treated for serious Gram-negative infection, and the case reports describe adverse events in that context (PMID 38702070, PMID 38601335).
3. No frequency estimates from case reports. Hyperpigmentation and Bartter-like syndrome were described in individual patients, so incidence remains unquantified in those sources (PMID 33014066, PMID 39649859).
4. No bridge from in vitro synergy to clinical cure. The triple-combination work reported laboratory activity against resistant isolates, not patient outcomes (PMID 32393492).
5. No in vivo confirmation of the protein-aggregation finding. The α-synuclein observation was made in a biophysical system and was not extended to treated patients (PMID 34118773).
6. No long-term follow-up of resistance carriage. Prevalence work characterised isolates at one centre without longitudinal patient outcomes (PMID 35740205).

Anyone with a clinical question about polymyxin B, colistin, or antibiotic resistance should raise it with a licensed physician or clinical pharmacist; this course describes published research only.

References

• Synthesis of Polymyxin-Inspired Peptidomimetics (Methods in Molecular Biology, 2025)
• Polymyxin B-induced Bartter syndrome (BMJ Case Reports, 2024)
• Polymyxin B accelerates the α-synuclein aggregation (Biophysical Chemistry, 2021)
• Inactivation of Polymyxin by Hydrolytic Mechanism (Antimicrobial Agents and Chemotherapy, 2019)
• Polymyxin B-Induced Skin Hyperpigmentation (Case Reports in Medicine, 2020)
• Inwardly rectifying potassium channels mediate polymyxin-induced nephrotoxicity (Cellular and Molecular Life Sciences, 2022)
• Polymyxin-induced neuromuscular weakness: a case report (Frontiers in Neurology, 2024)
• Prevalence and Molecular Characteristics of Polymyxin-Resistant Pseudomonas aeruginosa in a Chinese Tertiary Teaching Hospital (Antibiotics, 2022)
• Clinical Use of Polymyxin B (Advances in Experimental Medicine and Biology, 2019)
• Polymyxin-B induced Bartter-like syndrome: an unusual adverse effect (Annals of Medicine and Surgery, 2024)
• Emergent Polymyxin Resistance: End of an Era? (Open Forum Infectious Diseases, 2019)
• Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae (Antimicrobial Agents and Chemotherapy, 2020)